|
ИСТИНА |
Войти в систему Регистрация |
Интеллектуальная Система Тематического Исследования НАукометрических данных |
||
Co-delivery of Paclitaxel and Etoposide Prodrug by Human Serum Albumin and PLGA nanoparticles: synergistic cytotoxicity in brain tumor cellsстатья Исследовательская статья
- Авторы: Kovshova Tatyana, Mantrov Sergey, Boiko Svetlana, Malinovskaya Julia, Merkulova Maria, Osipova Nadezhda, Moiseeva Natalia, Akimov Mikhail, Dudina Polina, Senchikhin Ivan, Ermolenko Yulia, Gelperina Svetlana
- Журнал: Journal of Microencapsulation
- Год издания: 2023
- Издательство: Taylor & Francis
- Местоположение издательства: United Kingdom
- DOI: 10.1080/02652048.2023.2188943
- Аннотация: The aims of this study were to develop co-delivery systems of paclitaxel (PTX) and etoposide prodrug (4´-O-benzyloxycarbonyl-etoposide, ETP-cbz) based on non-cross-linked human serum albumin (HSA) and poly(lactide-co-glycolide) nanoparticles and to evaluate the synergistic potential of these drugs in vitro. The nanoformulations were prepared by the high-pressure homogenization technique and characterized using DLS, TEM, SEM, AFM, HPLC, CZE, in-vitro release, and cytotoxicity in human and murine glioma cells. All nanoparticles had 90-150 nm in size and negative ζ-potentials. The Neuro2A cells were the most sensitive to both HSA- and PLGA-based co-delivery systems (IC50 0.024 µM and 0.053 µM, respectively). The drugs’ synergistic effect (combination index < 0.9) was observed in the GL261 cells for both types of the co-delivery formulations and in the Neuro2A cells for the HSA-based system. These nanodelivery systems may be useful to improve combination chemotherapy for brain tumor treatment. To our knowledge, this is the first report describing the non-cross-linked HSA-based co-delivery nanosuspension which was prepared using nab™ technology.
- Добавил в систему: Ковшова Татьяна Сергеевна